How to buy Illumina stock (ILMN)

Our top picks for where to buy Illumina stock

Buy Illumina stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

AS SEEN ON:

Illumina is a diagnostics & research business based in the US. Illumina shares (ILMN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $135.27 – a decrease of 0.55% over the previous week. Illumina employs 10,590 staff and has a trailing 12-month revenue of around $4.4 billion.

Illumina stock price (NASDAQ: ILMN)

Use our graph to track the performance of ILMN stocks over time.

Illumina shares at a glance

• Key figures

Information last updated 2024-12-25.

Latest market close	$135.27
52-week range	$97.36 - $156.66
50-day moving average more info button	$143.44
200-day moving average more info button	$126.14
Wall St. target price	$163.52
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-9.96

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy Illumina stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Illumina price performance over time

Historical closes compared with the close of $134.96 from 2024-12-26

1 week (2024-12-20)	-0.78%
1 month (2024-11-27)	-6.51%
3 months (2024-09-27)	3.72%
6 months (2024-06-28)	29.30%

1 year (2023-12-28)	-5.04%
2 years (2022-12-28)	-27.29%
3 years (2021-12-28)	369.7179
5 years (2019-12-27)	323.2393

Is Illumina stock undervalued or overvalued?

Valuing Illumina stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Illumina's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Illumina's PEG ratio

Illumina's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.622. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Illumina's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Illumina's EBITDA

Illumina's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $730 million.

The EBITDA is a measure of a Illumina's overall financial performance and is widely used to measure a its profitability.

Illumina financials

Revenue TTM	$4.4 billion
Operating margin TTM	23.98%
Gross profit TTM	$3.1 billion
Return on assets TTM	2.62%
Return on equity TTM	-39.51%
Profit margin	-36.11%
Book value	$13.45
Market Capitalization more info button	$21.4 billion

TTM: trailing 12 months

Illumina share dividends

We're not expecting Illumina to pay a dividend over the next 12 months.

Have Illumina's shares ever split?

Illumina's shares were split on a 1028:1000 basis on 24 June 2024 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1028 shares. This wouldn't directly have changed the overall worth of your Illumina shares – just the quantity. However, indirectly, the new 2.7% lower share price could have impacted the market appetite for Illumina shares which in turn could have impacted Illumina's share price.

Illumina share price volatility

Over the last 12 months, Illumina's shares have ranged in value from as little as $97.3638 up to $156.66. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Illumina's is 1.131. This would suggest that Illumina's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Illumina overview

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

Frequently asked questions

What percentage of Illumina is owned by insiders or institutions?
Currently 0.27% of Illumina shares are held by insiders and 103.882% by institutions. How many people work for Illumina?
Latest data suggests 10,590 work at Illumina. When does the fiscal year end for Illumina?
Illumina's fiscal year ends in December. Where is Illumina based?
Illumina's address is: 5200 Illumina Way, San Diego, CA, United States, 92122 What is Illumina's ISIN number?
Illumina's international securities identification number is: US4523271090 What is Illumina's CUSIP number?
Illumina's Committee on Uniform Securities Identification Procedures number is: 452327109